A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

Launched by SHIONOGI · Jul 12, 2023

Keywords

ClinConnect Summary

This clinical trial is testing a medication called redasemtide to see if it can help adults who have had an acute ischemic stroke, which happens when a blood clot blocks blood flow to the brain. The trial is currently recruiting participants aged 65 to 74 who are able to start treatment within 25 hours of their stroke. To be eligible, participants should not be suitable for certain standard treatments like clot removal and should have a specific score on a stroke severity scale, indicating the level of their condition.

Participants in the study will receive either redasemtide or a placebo (a substance with no active medication) and will be monitored for safety and effectiveness. It's important to note that some people may not qualify for the study, such as those with severe neurological issues, recent serious health problems, or certain blood pressure and blood sugar levels. This trial aims to find out if redasemtide can improve outcomes for stroke patients and help them recover better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Able to initiate study intervention within 25 hours of stroke onset
• • Determined by the investigator to not be eligible for recanalization thrombolysis or endovascular recanalization therapy (that is, mechanical thrombectomy, local fibrinolytic therapy) for the current stroke.
• • Baseline NIHSS score of 8 to 22 (inclusive) and stable, defined as absence of an increase or decrease of ≥ 4 points within ≥ 1 hour to ≤ 3 hours between screening and baseline assessment of NIHSS score.
• • Medically stable at the time of enrollment except for primary disease and complications associated with it, according to the judgment of the investigator. In addition, hospitalization during the Follow-up Period is not anticipated, and the participant appears likely to be able to complete the study. Medically stable is defined as disease not requiring significant change in therapy for 3 months following enrollment.
• Exclusion Criteria:
• • Any disease or neurological disorder that, in the opinion of the investigator, would interfere with the conduct of the study
• • A severe decrease in consciousness level (defined as NIHSS item 1a score 3: Not alert, responds only with reflex motor or autonomic effects, or totally unresponsive, flaccid, and areflexic)
• • Disability corresponding to a mRS score of ≥ 2 before the onset of stroke
• • A history of stroke (excluding transient ischemic attack), history of or current intracranial hemorrhage, or head trauma that caused neurological effects within 90 days prior to obtaining informed consent
• • Participants with an ischemic stroke in cerebellum and/or brain stem as the main infarction site
• • Diagnosis of a current transient ischemic attack
• • Unable to undergo either CT or MRI
• • Considered by the investigator to be inappropriate to participate due to a history or complication of serious cardiovascular disease within 1 month of screening (for example, history of acute myocardial infarction, current acute myocardial infarction, uncontrollable heart failure, infective endocarditis requiring treatment, or acute aortic dissection, or requiring or likely to require hospitalization for severe arrhythmia during the study)
• • Blood glucose level \< 50 or \> 400 milligrams/deciliter after glycemic control
• • Systolic blood pressure ≥ 220 millimeters of mercury (mmHg) or diastolic blood pressure ≥ 120 mmHg after antihypertensive treatment
• • Sensitivity to any of the study interventions, or components thereof, or clinically significant drug or other severe allergy that, in the opinion of the investigator, contraindicates participation in the study
• • Use of prohibited concomitant medications or therapies listed in the protocol for the treatment of current AIS
• • Participants who have previously received redasemtide
• • Participants who have received any investigational product within 90 days of screening
• • Note: Other protocol-defined Inclusion/Exclusion criteria may apply.